THE US Food and Drug Administration has announced additional steps to encourage generic competition, with measures including "reducing gaming by branded companies that can delay generic drug entry".
The FDA is also committed to resolving scientific and regulatory obstacles making it difficult to win approval for generic versions of certain complex drugs, and improving the predictability of its generic review process to speed approval times.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jan 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jan 18
